General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Tricog Health(SIGNIFICANT), Roche Diagnostics(SIGNIFICANT), Cytokinetics(MODEST), Eli Lilly and Company(SIGNIFICANT), Rivus(MODEST), Palomarin Inc.(NONE), Pieces Technologies(MODEST), Novo Nordisk Inc.(SIGNIFICANT), Edwards Lifesciences(MODEST), Medtronic(MODEST), Alleviant(MODEST), Axon therapies(MODEST) RESEARCH/RESEARCH GRANTS: Gilead Sciences, Inc. (NONE), Applied Theraputics(NONE) OTHER FINANCIAL BENEFIT: Pfizer Inc(NONE), Merck & Co., Inc.(NONE), Merck & Co., Inc.(MODEST)

View Full Disclosure